Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
Selma Blair's son helped her shave her head following multiple sclerosis diagnosis
on June 15, 2019 at 7:09 pm
Selma Blair hasn't been shy to share her health journey since being diagnosed with multiple sclerosis. The actress was diagnosed with the disease in August 2018 which is chronic and typically ... […]
Bike MS Raises Money, Fun In Multiple Sclerosis Community
on June 15, 2019 at 8:46 am
DENVER (CBS4) – Bike MS is a 2-day, 150-mile bike ride that raises money for the National MS Society. “This year’s goal is $3.2 million. We’re going to have somewhere in the neighborhood ... […]
Multiple Sclerosis: Symptoms, Management & New Research
on June 14, 2019 at 11:33 am
Multiple sclerosis (MS) is a disease that affects the central nervous system: the brain and spinal cord. In MS, the body's immune system mistakenly attacks myelin, the protective coat surrounding ... […]
True or False: Test Your Knowledge About Multiple Sclerosis
on June 12, 2019 at 11:48 am
Multiple sclerosis (MS) affects an estimated 1 million people in the United States. It’s the most common neurological disease in young adults, usually developing between the ages of 20 and 40 — just ... […]
FDA Approves 1st Drug for Aggressive Multiple Sclerosis
on June 12, 2019 at 10:13 am
U.S. regulators have approved the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk. The Food and Drug Administration approved Ocrevus ... […]
Ask the Expert: What Do I Need to Know About How Multiple Sclerosis Affects the Brain?
on June 12, 2019 at 8:08 am
1. Multiple sclerosis (MS) is a condition of the central nervous system, which includes the brain, spinal cord, and optic nerve. How does MS affect these areas, and what are some of the issues MS ... […]
High-dimensional detection of imaging response to treatment in multiple sclerosis
on June 9, 2019 at 4:06 pm
Changes on brain imaging may precede clinical manifestations or disclose disease progression opaque to conventional clinical measures. Where, as in multiple sclerosis, the pathological process has a ... […]
Model explores how statins alter multiple sclerosis outcomes
on June 7, 2019 at 10:52 am
(HealthDay)—Simvastatin's beneficial effects on clinical outcomes and brain atrophy in patients with multiple sclerosis (MS) are largely independent of cholesterol levels, according to a post ... […]
Scientists edge closer to root causes of multiple sclerosis
on June 6, 2019 at 11:38 am
An international team of researchers led by the University of British Columbia has made a scientific advance they hope will lead to the development of preventative treatments for multiple ... […]
via Bing News